Tumor PD-L1 expression is positively associated with response to anti-PD-1 blockade. First FDA approved as predictive biomarker for Pembrolizumab treatment of NSCLC in 2015, it is widely used as predictive biomarker for anti-PD1 blocking ICIs (251). Here, PDCD1 is linked to non-small cell lung carcinoma.